Xbrane Biopharma Zukünftiges Wachstum

Future Kriterienprüfungen 6/6

Xbrane Biopharma wird ein jährliches Gewinn- und Umsatzwachstum von 130.2% bzw. 61.1% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 135.8% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 59% betragen.

Wichtige Informationen

130.2%

Wachstumsrate der Gewinne

135.8%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	45.0%
Wachstumsrate der Einnahmen	61.1%
Zukünftige Eigenkapitalrendite	59.0%
Analystenabdeckung	Low
Zuletzt aktualisiert	28 Oct 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Even With A 30% Surge, Cautious Investors Are Not Rewarding Xbrane Biopharma AB (publ)'s (STO:XBRANE) Performance Completely

Sep 30

Market Cool On Xbrane Biopharma AB (publ)'s (STO:XBRANE) Revenues Pushing Shares 34% Lower

Aug 05

Market Might Still Lack Some Conviction On Xbrane Biopharma AB (publ) (STO:XBRANE) Even After 32% Share Price Boost

Jun 21

Xbrane Biopharma AB (publ)'s (STO:XBRANE) Intrinsic Value Is Potentially 28% Above Its Share Price

Feb 10

We Think Xbrane Biopharma (STO:XBRANE) Can Afford To Drive Business Growth

Jan 12

Gewinn- und Umsatzwachstumsprognosen

OM:XBRANE - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (SEK Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	844	550	N/A	N/A	2
12/31/2025	460	40	N/A	33	2
12/31/2024	299	-176	N/A	-74	1
9/30/2024	200	-305	-344	-309	N/A
6/30/2024	192	-341	-431	-419	N/A
3/31/2024	191	-361	-465	-463	N/A
12/31/2023	239	-322	-423	-407	N/A
9/30/2023	189	-285	-467	-441	N/A
6/30/2023	144	-246	-427	-390	N/A
3/31/2023	112	-189	-340	-296	N/A
12/31/2022	58	-169	-254	-194	N/A
9/30/2022	43	-146	-216	-139	N/A
6/30/2022	32	-147	-229	-127	N/A
3/31/2022	15	-172	-282	-182	N/A
12/31/2021	11	-183	-297	-220	N/A
9/30/2021	8	-213	-278	-227	N/A
6/30/2021	5	-219	-286	-268	N/A
3/31/2021	3	-215	-160	-147	N/A
12/31/2020	N/A	-218	-242	-238	N/A
9/30/2020	N/A	-222	-169	-165	N/A
6/30/2020	N/A	-210	-146	-145	N/A
3/31/2020	N/A	-204	-180	-179	N/A
12/31/2019	N/A	-188	-150	-149	N/A
9/30/2019	5	-154	-118	-117	N/A
6/30/2019	7	-56	0	2	N/A
3/31/2019	12	-40	0	2	N/A
12/31/2018	20	-13	45	47	N/A
9/30/2018	25	0	-8	-4	N/A
6/30/2018	23	-69	N/A	-47	N/A
3/31/2018	23	-45	N/A	-36	N/A
12/31/2017	21	-45	N/A	-37	N/A
9/30/2017	11	-35	N/A	-35	N/A
6/30/2017	11	-34	N/A	-39	N/A
3/31/2017	6	-31	N/A	-41	N/A
12/31/2016	N/A	-28	N/A	-39	N/A
9/30/2016	0	-24	N/A	-37	N/A
6/30/2016	0	-19	N/A	-27	N/A
3/31/2016	1	-16	N/A	-19	N/A
12/31/2015	0	-12	N/A	-12	N/A
9/30/2015	2	-8	N/A	-5	N/A
12/31/2014	2	-3	N/A	-3	N/A
12/31/2013	0	-2	N/A	N/A	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: XBRANE wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (1.2%).

Ertrag vs. Markt: XBRANE wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: XBRANE wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: XBRANEDie Einnahmen des Unternehmens (61.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Swedish (-0.04% pro Jahr).

Hohe Wachstumseinnahmen: XBRANEDie Einnahmen des Unternehmens (61.1% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: XBRANEDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich sehr hoch sein (59%).

Xbrane Biopharma Zukünftiges Wachstum

Future Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates upgraded to kr0.095 loss

Consensus EPS estimates fall by 35%

Consensus revenue estimates fall by 28%

Forecast breakeven date pushed back to 2025

Price target increased by 37% to kr219

Consensus revenue estimates increase by 14%, EPS downgraded

Recent updates

New major risk - Financial position

Xbrane Biopharma AB (publ), Annual General Meeting, May 05, 2025

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Xbrane Biopharma AB (publ) to Report Q1, 2025 Results on May 08, 2025

Xbrane Biopharma AB (publ) to Report Fiscal Year 2024 Results on Feb 21, 2025

Xbrane Biopharma AB (publ) to Report Fiscal Year 2024 Results on Feb 21, 2025

Even With A 30% Surge, Cautious Investors Are Not Rewarding Xbrane Biopharma AB (publ)'s (STO:XBRANE) Performance Completely

Xbrane Provides Update from Scientific Advice with US FDA on Xdivane™ (Opdivo® Biosimilar Candidate)

Consensus EPS estimates upgraded to kr0.095 loss

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Market Cool On Xbrane Biopharma AB (publ)'s (STO:XBRANE) Revenues Pushing Shares 34% Lower

Market Might Still Lack Some Conviction On Xbrane Biopharma AB (publ) (STO:XBRANE) Even After 32% Share Price Boost

First quarter 2024 earnings: Revenues miss analyst expectations

Xbrane Biopharma AB (publ) to Report Q2, 2024 Results on Aug 28, 2024

Xbrane Biopharma AB (Publ) Appoints Kristoffer Bissessar Was Elected as New Director

Consensus EPS estimates fall by 35%

New minor risk - Financial position

New major risk - Shareholder dilution

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Market cap size

Xbrane Biopharma AB (Publ) Announces Appointment of Nomination Committee

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Xbrane Biopharma AB (publ) Focuses on Development Portfolio and Introduces A Cost-Savings Scheme

Xbrane Biopharma AB (publ) to Report First Half, 2024 Results on Jul 17, 2024

Xbrane Biopharma AB (Publ) Presents Nomination Committee

Chief Executive Officer recently sold kr272k worth of stock

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 28%

Forecast breakeven date pushed back to 2025

Xbrane Biopharma AB (publ) to Report Fiscal Year 2023 Results on Mar 27, 2024

Price target increased by 37% to kr219

Consensus revenue estimates increase by 14%, EPS downgraded

Price target increased by 13% to kr253

New major risk - Financial position

Chief Executive Officer recently bought kr150k worth of stock

COO, Head of Biosimilars & Deputy CEO recently bought kr817k worth of stock

Xbrane Biopharma AB (publ) to Report Fiscal Year 2023 Results on Feb 29, 2024

CFO & Head of Investor Relations recently bought kr236k worth of stock

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Full year 2022 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates decrease by 15%

Now 22% undervalued

Xbrane Biopharma AB (publ) to Report Q1, 2023 Results on May 04, 2023

Insider recently bought kr156k worth of stock

Chief Executive Officer recently bought kr175k worth of stock

Xbrane Provides an Update on Ranibizumab Biosimilar Candidate FDA Filing

Forecast breakeven date pushed back to 2024

Price target increased to kr173

STADA Arzneimittel AG and Xbrane Biopharma AB Secures EU Approval for Ximluci (Ranibizumab) Biosimilar Referencing Lucentis

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Xbrane Biopharma AB (publ) to Report First Half, 2023 Results on Aug 31, 2023

STADA Arzneimittel AG and Xbrane Biopharma AB (publ) Announce European Medicines Agency’s Committee for Medicinal Products for Human Use Adopts Positive Opinion for Ximluci

Xbrane Biopharma AB (publ), Annual General Meeting, May 04, 2023

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Xbrane Biopharma AB (publ) to Report Q1, 2023 Results on May 31, 2023

Xbrane Biopharma AB (publ) to Report Fiscal Year 2022 Final Results on Mar 31, 2023

Xbrane Provides Update on Ranibizumab Biosimilar Candidate FDA Filing

Chief Executive Officer recently sold kr1.0m worth of stock

An unknown buyer acquired an unknown minority stake in Xbrane Biopharma AB (publ) (OM:XBRANE) from Martin Amark and Siavash Bashiri.

Head of Regulatory Affairs recently bought kr104k worth of stock

Chief Technology Officer recently bought kr699k worth of stock

Is Xbrane Biopharma (STO:XBRANE) In A Good Position To Deliver On Growth Plans?

Xbrane Biopharma AB (publ) Provides Update on Ranibizumab Biosimilar Candidate FDA Filing

Price target increased to kr235

Chief Executive Officer recently sold kr496k worth of stock

Xbrane Biopharma AB (Publ) Announces Positive Top-Line Results from the Pivotal Phase III Equivalence Trial for Xlucane™ - A Biosimilar Candidate to Lucentis

Xbrane Biopharma AB (publ)(OM:XBRANE) dropped from OMX Nordic Small Cap Index

We Think Xbrane Biopharma (STO:XBRANE) Needs To Drive Business Growth Carefully